Published in Transplant Proc on June 01, 1998
Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg (1999) 1.24
Mixed chimerism and split tolerance: mechanisms and clinical correlations. Chimerism (2012) 0.83
Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients: improved graft function and higher graft survival. Chimerism (2013) 0.76
Kidney transplantation with bone marrow augmentation: five-year outcomes. Transplant Proc (2001) 0.76
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Immunology taught by viruses. Science (1996) 4.82
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 4.26
Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med (1977) 3.48
On immunological memory. Annu Rev Immunol (1996) 3.21
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev (1997) 2.58
Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation (1991) 2.32
Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery (1976) 1.84
Fractionated total lymphoid irradiation as preparative immunosuppression in high risk renal transplantation: clinical and immunological studies. Ann Surg (1982) 1.44
Augmentation of chimerism in whole organ recipients by simultaneous infusion of donor bone marrow cells. Transplant Proc (1995) 1.24
Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc (1970) 1.22
Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation (1983) 1.19
Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation (1995) 1.19
Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc (1971) 1.16
Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation (1994) 1.16
The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest (1997) 1.02
Combined bone marrow and whole organ transplantation from the same donor. Transplant Proc (1994) 1.02
Combined simultaneous kidney/bone marrow transplantation. Transplantation (1995) 0.98
High-dose donor bone marrow infusions to enhance allograft survival: the effect of timing. Transplantation (1997) 0.95
Engraftment of normal murine marrow into nonmyeloablated host mice. Blood Cells (1994) 0.91
Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc (1996) 0.90
Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. Ann Surg (1983) 0.86
Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. Transplantation (1997) 0.84
The future of transplantation: with particular reference to chimerism and xenotransplantation. Transplant Proc (1997) 0.83
Use of low doses of homozygous allogeneic bone marrow cells to induce tolerance with antilymphocyte serum (ALS): tolerance by intraorgan injection. Transplant Proc (1971) 0.82
Use of antilymphocyte serum in the induction of immunological tolerance to tissue allografts. Fed Proc (1970) 0.82
Chimerism after whole organ transplantation: its relationship to graft rejection and tolerance induction. Curr Opin Nephrol Hypertens (1994) 0.79
Documentation in bone-marrow-augmented organ recipients of the presence of dendritic cell progenitors of donor origin. Transplant Proc (1997) 0.77
Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments. Transplant Proc (1972) 0.77
Total lymphoid irradiation: basic and clinical studies in transplantation immunity. Prog Clin Biol Res (1986) 0.77
Evolution of liver transplantation. Hepatology (1982) 19.54
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Changes in blood coagulation. Arch Surg (1966) 3.22
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Fungal infections in liver transplant recipients. Transplantation (1985) 3.07
De novo malignant tumors in organ transplant recipients. Transplant Proc (1971) 3.03
Experience with 150 liver resections. Ann Surg (1983) 3.01
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00
Death after transplantation; an analysis of sixty cases. Am J Med (1967) 2.99
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev (1971) 2.94
Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92
Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Liver transplantation in adults. Hepatology (1982) 2.89
Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80
Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis (1988) 2.76
Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts. Ann Intern Med (1968) 2.72
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
Growth-stimulating factor in regenerating canine liver. Lancet (1979) 2.61
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Portal vein grafts in hepatic transplantation. Surg Gynecol Obstet (1985) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
Studies of blood flow and ultrastructural changes in rejecting and nonrejecting canine orthotopic liver homografts. Surgery (1968) 2.58
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Liver transplantation, 1980, with particular reference to cyclosporin-A. Transplant Proc (1981) 2.49
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus. Ann Surg (1978) 2.48